Cingulate (CING) EBIT Growth (1y) (2022 - 2026)
Cingulate (CING) EBIT Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 8.32% |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 19.82% |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 145.20% |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | 10.14% |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 269.85% |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | 1,528.74% |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | -336.63% |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 99.51% |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | -36.55% |
| 10 | Cingulate | 72.13 Mn | 72.13 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.45% |
| Dec 31, 2025 | 10.02% |
| Sep 30, 2025 | -82.68% |
| Mar 31, 2025 | -25.70% |
| Dec 31, 2024 | 8.66% |
| Sep 30, 2024 | 42.92% |
| Jun 30, 2024 | 49.61% |
| Mar 31, 2024 | 23.42% |
| Dec 31, 2023 | -51.89% |
| Sep 30, 2023 | -44.89% |
| Jun 30, 2023 | -57.14% |
| Mar 31, 2023 | 23.14% |
| Dec 31, 2022 | -69.05% |
| Sep 30, 2022 | 74.03% |
| Jun 30, 2022 | -184.60% |
| Mar 31, 2022 | -276.60% |